WORDS FROM THE ISH CHAIR OF COUNCIL
|
|
|
The International Society of Hematology (ISH) will return to in-person meetings this year on October 6-8 along with the Spanish Society of Hematology (Sociedad Española de Hematología y Hemoterapia: SEHH). After interruptions derived from the COVID 19 pandemic, we are back on our feet and will celebrate our 38th World ISH Congress. Our Spanish friends and colleagues have chosen the splendid city of Barcelona as the venue of the joint meeting, and we are confident that this will be an unforgettable hematology world congress. A solid and state of the art academic content will be presented.
Please save the date and be ready for this outstanding combined meeting. It will be a pleasure seeing you in Barcelona in October!
Keep safe,
David Gómez-Almaguer MD
ISH Chair of Council
|
|
|
Second generation FLT3 inhibitors improve upon 7+3
The potent FLT3-ITD oral inhibitor quizartinib seem to be effective among with FLT3-ITD positive AML. The study presented at EHA showed that this compound in combination with standard induction chemotherapy and as a single agent for up to 36 months doubles median overall survival (31.9 months) in AML patients without severe toxicity. Is this the new standard of care for this kind of AML patients? How will this drug come into play with midostaurin the first FLT3 inhibitor? We will like to see confirmatory data and compare between generations.
|
|
SAVE THE DATE BARCELONA OCTOBER 2022
The 38th World Congress of the International Society of Hematology will be taking place during the annual Spanish hematology meeting from the Sociedad Española de Hematología y Hemoterapia in the beautiful city of Barcelona, October 6-8, 2022. The meeting will be hybrid taking place both in person and virtually. We’ll keep you posted regarding registration dates, abstract deadlines, and all meeting details soon.
|
|
JOIN THE ISH
Become an ISH Delegate! Join the International Society of Hematology and connect with other professionals from all around the world who are interested in all areas of research, education, and healthcare policy.
Benefits of including an ISH member include
- Opportunity to collaborate in ISH Committees
- Submit and sponsor abstracts to the ISH World Congress
- Reduced registration fee for the ISH Congress and meetings
- Reduced author publishing fees for HEMATOLOGY journal
Want to contribute to the newsletter? Write to us atnews@iadish.org
|
|
|
Hematology is the official journal of the ISH published online by Taylor Francis. It is an international open access journal publishing original research and reviews in the field of general hematology, including oncology, pathology, biology, clinical research, and epidemiology.
Hematology aims to bridge the interests and practice of both those carrying out laboratory work and those whose main inclination is patient care. ISH members have a reduced author publishing fee to Hematology.
|
|
|
|
|